Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026

Contributed by: Business Wire

Logo

Tags

Technology

Health Technology

Professional Services

Biotechnology

Data Analytics

Pharmaceutical

Health

Data Management

Oncology

Artificial Intelligence

ESMO Congress 2026

More Like This

Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025

Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types

First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer

Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications

Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy

First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation